Close to the Heart: The Importance of Recognizing Cardiovascular Risk in Type 2 Diabetes
Industry Webcast Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC; Not for CME/CE Credit
March 19, 2021 | 12:25 PM - 1:10 PM ET
The objective of this program is to communicate the importance of addressing cardiovascular risk in patients with type 2 diabetes. The program will cover data on prevalence, morbidity, mortality, and intensive versus conventional glucose lowering on macrovascular complications. In addition, the program will review guidance from leading medical associations that is based upon completed cardiovascular outcome trials of antihyperglycemic medications in patients with type 2 diabetes.
This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.